ENPICOM announced the company has entered into a service agreement with Neogene Therapeutics to grant the company access to ENPICOM’s cloud-based IGX Platform to manage, organize, and analyze T cell sequencing data. ENPICOM has additionally developed a number of customizations making sure that the platform’s functionality fits Neogene’s specific data handling workflow to help Neogene’s research team leverage the full potential of their immune repertoire data.
"We are extremely proud to add Neogene Therapeutics to our IGX Platform customer base. Their recent $110 million Series A shows how important this new type of immunotherapy has become in the last few years," said Jos Lunenberg, CEO of ENPICOM.
"ENPICOM and the Neogene team have been collaborating for several years on various projects. ENPICOM has always been a thoughtful and highly reliable partner. It is a pleasure to utilize their innovative and unique IGX Platform," Dr. Carsten Linnemann, CEO of Neogene Therapeutics, said.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
Since immune repertoire sequencing implies the generation of large amounts of data, there is a need for specific expertise to efficiently manage and fully exploit the potential of the data collected. ENPICOM’s IGX Platform provides Neogene with a solution to manage and annotate T cell sequencing data.
The IGX Platform comes with data management features and a user interface out of the box. Its modular, flexible structure allows for further enhancements and customizations. The custom robust workflow of the IGX Platform uniquely positions it to support high-throughput studies required to power Neogene's research in personalized T cell therapies.